[ Inside the business ]

A stock analysis

A · Agilent Technologies, Inc.

Laboratory analytical instruments. Growing 8%. Keeps 22¢ of every dollar.

Watch: a leadership change, growth that has stopped speeding up.

The future, in 7 questions

Priced in: 2.6× sales in 5 yrs. Evidence: sales +8% · 22¢ profit/$1.

01 What's priced in?2.6× sales in 5 yrs
Sales now$7.4B
Needed in 5 yrs$19.4B
Backlog$437M
02 Is the wave rising?Biomanufacturing · 0.8×
'20'21'22'23'24'2535
#8 of 20 mentioning it
03 Will customers keep buying?Sales +8%, steady
No customer over 10%
Backlog $437M · under 0.1× salesPrepaid $822MSales +8%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 22¢ per $1, rising
'21'22'23'24'2522¢
Before running costs: 54% → 52%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −1.9%/yrDebt $3.9B
07 What could break it?2 to watch
  • Growth peaked
  • Moves strongly with the S&P 500

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth peaked.

Sales growth +7%, +10%, then +8% vs. a year ago. A leadership change was filed on Nov 20.

What could go wrong

Few warning signs.

It has moved 1.1× the market. In the 2008 crisis it fell 62% while the market fell 51%. Debt is moderate.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

41% Agilent CrossLab.

Agilent CrossLab 41% · Life Sciences and Diagnostics Markets 40% · Applied Markets 19%

Where each dollar goes

22¢ profit.

46¢ to make what it sells, 32¢ on research and overhead, 22¢ left over. Revenue $7.4B in the last 12 months.

Its market

0.6× the economy.

The government expects its industry, navigational, measuring, electromedical, and control instruments manufacturing, to grow 1.1% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators. Cash covers 112¢ of each $1 of profit.

Competitive advantage

8 of 10 years.

Returns beat its 9.6% cost of capital in 8 of the last 10 years. Gross margin went from 52% to 52%.

Future bets

$146M committed.

Promised to suppliers, per its latest 10-Q. Plus $485M a year on research (7% of sales). Stakes in other companies: $49M.

All figures from Agilent Technologies, Inc.'s SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.